Biotechnology Get all the latest news from the field of biotechnology and its many applications, including testing, treatment, and pharmaceuticals. This category includes research, clinical, and study results, as well as stories about the newest breakthroughs in the industry. Read stories about upcoming conferences and symposiums, along with releases regarding patents, legal activity, company performance, and market analysis.

Latest

07:30 ET New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting...


Dec 07, 2019, 09:00 ET Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American...


Dec 07, 2019, 09:00 ET More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier...


Dec 07, 2019, 08:00 ET Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...


Dec 07, 2019, 07:33 ET Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3...


Dec 07, 2019, 07:30 ET IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical...


Dec 07, 2019, 02:40 ET Janssen to Acquire Investigational Bermekimab from XBiotech

Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire...


Dec 06, 2019, 15:42 ET Grifols presents its latest Alzheimer's clinical trial data

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging...


Dec 06, 2019, 15:25 ET FDA sends warning to companies for offering unapproved umbilical cord blood products that may put patients at risk

The U.S. Food and Drug Administration has warned Liveyon Labs Inc. (Liveyon Labs) and Liveyon LLC, of Yorba Linda, California, and their presidents...


Dec 06, 2019, 14:31 ET FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved...


Dec 06, 2019, 12:20 ET Luminex Corporation Declares Fourth Quarter Cash Dividend

Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the fourth quarter of 2019 ...


Dec 06, 2019, 11:30 ET Results from the PROTECT VIII Extension Study with Jivi® Published in Haemophilia

Bayer today announced the publication of an analysis of the PROTECT VIII extension study in which a subset of 33 patients with hemophilia A who...


Dec 06, 2019, 09:30 ET 2019 Biotechnology Research Review: CRISPR, Spheroids for Drug Development, Luciferase-based High-throughput Screening Assays, and More

The "2019 Biotechnology Research Review" report has been added to ResearchAndMarkets.com's offering. Several significant developments have aided and...


Dec 06, 2019, 09:00 ET Enzychem Lifesciences announces collaborative Material Transfer Agreement (MTA) with the Armed Forces Radiobiology Research Institute (AFRRI) for the Development of a Radiation Medical Countermeasure.

Enzychem Lifesciences, a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, announced that ...


Dec 06, 2019, 08:00 ET Global Gene Therapy Market Growth, Company Profiles, Clinical trials and Forecasts to 2022 - ReportsnReports

The global gene therapy market is forecast to hit $363 million by 2022. Strengthened by recent approvals of Kymriah, Yescarta and Luxturna in the US, ...


Dec 06, 2019, 08:00 ET Dr. George Syrmalis, appointed as the New Chairman of the Board for The IQ Group Global Member Company, GBS Inc.

Founder and CEO of The iQ Group Global, Dr. George Syrmalis has been appointed as Chairman of the Board for GBS Inc., it was announced today. Dr...


Dec 06, 2019, 07:30 ET Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage...


Dec 06, 2019, 07:26 ET Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...


Dec 06, 2019, 07:00 ET Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3...


Dec 06, 2019, 07:00 ET Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...


Dec 06, 2019, 07:00 ET 3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug...


Dec 06, 2019, 07:00 ET PRC NHC Issues New Policy on Cord Blood Banks, Implementation Rules To Be Provided

Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem...


Dec 06, 2019, 02:00 ET BC Platforms Partners with Leading European Genomics Service Provider Center Life & Brain to Expand Genotyping Services Across Europe

BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a partnership with Life & Brain Genomics, a ...


Dec 05, 2019, 17:47 ET Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.

The U.S. Food and Drug Administration has been investigating the presence of genotoxic impurities, called nitrosamines, in some types of drugs. Over...


Dec 05, 2019, 15:29 ET FDA approves first generics of Gilenya

The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of...